EMD-52520

Single-particle
2.6 Å
EMD-52520
3D View Gallery
Deposition: 13/01/2025
Map released: 16/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-52520

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9hz5 summary report (pdf.gz) Map-9hz5 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Pre-clinical characterization of novel multi-client inhibitors of Sec61 with broad anti-tumor activity

EMD-52520

Single-particle
2.6 Å
EMD-52520
3D View Gallery
Deposition: 13/01/2025
Map released: 16/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Ovis aries
Sample: Sec61 translocon complex with small molecule
Fitted models: 9hz5

Deposition Authors: Shahid R, Paavilainen VO
Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity.
Lowe E, Anderl JL , Bade D, Delgado-Martin C, Dong C, Fan RA, Fang Y, Jiang J, Johnson HWB, Kempema A, McGilvray P, McMinn D, Millare B, Muchamuel T, Poweleit N, Qian Y, Rehan S , Scapin G, Sugahara A, Tranter D, Tuch B, Wang J, Wang L, Whang JA, Zuno-Mitchell P, Paavilainen VO, Park E, Taunton J, Kirk CJ, Anand NK
(2025) J Pharmacol Exp Ther , 392 , 103634 - 103634
PUBMED: 40669140
DOI: doi:10.1016/j.jpet.2025.103634
ISSN: 1521-0103
Grant Support: